Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies

The summary for the Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control NCBDDD, which is the U.S. government agency offering this grant.
Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies: Red blood cell (RBC) transfusions are an important part of medical care for many patients with thalassemia or sickle cell disease. Some patients never need a transfusion, others may have infrequent or intermittent needs, and still others may need chronic transfusions every few weeks. Determining which patients need to receive transfusions, when and how often they need to receive them, and what steps minimize complications from the transfusions may lead to improved health outcomes. For individuals with thalassemia, specifically, there are no universal screening programs in the U.S. and so many patients and their health care providers are unaware of their diagnosis until overt clinical signs begin to manifest. The initiation of transfusion may be delayed until complications appear. If the diagnosis is never made, patients continue living without the benefits that transfusions could provide. Iron chelation therapy is indicated for all transfused patients when iron measures indicate concentrations that exceed threshold levels. Red blood cell alloimmunization occurs when the immune system is exposed to foreign antigens on red blood cells that are different from its own. Frequent blood transfusions may also expose individuals to infectious agents that may be transmitted through blood. By improving the identification of people who have these conditions and may benefit from appropriately administered transfusions, the understanding of treatment for them, and the standardization of information that is available about them, therapeutic transfusions may be administered in ways that maximize their benefits and minimize their adverse effects. This NOFO aims to improve access to, coordination of, and continuity of health care for individuals with thalassemia or sickle cell disease which will lead to a decreased occurrence of transfusion-related complications, improved quality and increased length of life. These health care improvements will result from a multi-faceted approach that includes (1) identification of patients, families, communities, and providers who will benefit from increased knowledge about therapeutic transfusions and their potential complications, (2) development and dissemination of materials that will increase understanding of the diagnosis and management of these blood disorders, and (3) collection of biological specimens from individuals with thalassemia or sickle cell disease. This NOFO builds upon findings from the work completed as part of CDC-RFA-DD14-1406. In particular, (1) the difficulty in identifying any thalassemia patient in the U.S. and their health care provider prior to medical complications manifesting, other than those born in states where the condition is a part of the mandatory newborn screening panel, (2) the lack of standardized practices across, and sometimes within, clinical care settings and blood banks for transfusions of patients with thalassemia or sickle cell disease, (3) the need for dissemination of evidence- or consensus-based guidelines about best practices for transfusions, and (4) the room for improvement in increasing blood donation from communities most affected by thalassemia or sickle cell disease.
Federal Grant Title: Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies
Federal Agency Name: Centers for Disease Control NCBDDD (HHS-CDC-NCBDDD)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: CDC-RFA-DD19-1903
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.080
CFDA Descriptions: Information not provided
Current Application Deadline: May 3rd, 2019
Original Application Deadline: May 3rd, 2019
Posted Date: February 26th, 2019
Creation Date: February 26th, 2019
Archive Date: June 2nd, 2019
Total Program Funding: $3,750,000
Maximum Federal Grant Award: $375,000
Minimum Federal Grant Award: $50,000
Expected Number of Awards: 2
Cost Sharing or Matching: No
Last Updated: February 26th, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
Mary Hulihan
[email protected]
Grants Policy
Similar Government Grants
Sickle Cell Data Collection Program
Evaluation of Health Promotion and Prevention Programs for Blood Disorders
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Capacity Building for Sickle Cell Disease Surveillance
More Grants from the Centers for Disease Control NCBDDD
Surveillance of Congenital Heart Defects Among Children, Adolescents, and Adults
Surveillance of Muscular Dystrophies
Surveillance of Spina Bifida across the Lifespan
Implementing Evidence-Based Health Promotion Programs for Attention-Deficit Hyperactivity ...
Documenting outcomes associated with Persistent Tic Disorders (including Tourette Syndrome...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com